Abstract
INTRODUCTION
Hepatitis C virus (HCV) infection is one of the most fre quent etiologies of cirrhosis, and is therefore responsible for most of its complications, including hepatocellular carcinoma, which is the sixth most common cancer world wide [1] . Despite the recent advances in HCV therapy, the prevalence of advanced liver disease will continue to increase as well as the corresponding healthcare burden [2] . In Brazil, although the hepatitis C viremic prevalence is about 1%, only 15% of the estimated infected patients are diagnosed, usually with advanced fibrosis. This is partly explained by the scarcity of specialist centers compared with the societal needs. Of those who are diagnosed, only 60% receive specialized treatment [3, 4] . The stage of liver fibrosis in HCV patients is asso ciated with prognosis, and has a resulting impact on treatment strategy and followup. Liver biopsy (LB) is still the gold standard procedure for fibrosis assessment, but noninvasive new approaches have been strongly recommended for evaluation of fibrosis, mainly in HCV. They require less operator expertise, have no com plications and have good diagnostic accuracy [57] . The most extensively used noninvasive mechanical methods based on ultrasound are transient elastography (TE or FibroScan ® ) and acoustic radiation force impulse (ARFI) technology, Virtual Touch ® . There are several laboratorial markers in development, and validated scores such as aspartate aminotransferasetoplatelet ratio index (APRI) and FIB4 [based on age, platelet count, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], that are easily calculated with routine laboratory tests.
Use of liver biopsy has decreased following the intro duction of noninvasive tests, especially among chronic HCV patients [8] . Although, according to the recently published EASL Guideline for the evaluation of HCV patients, a perfect marker (AUROC > 0.90) for liver disease could not be achieved, the use of noninvasive tests reduce, but do not abolish the need for liver biopsy [8] . Many biological tests, including APRI, PGA index, Forns' index, Fibrotest, FIB4 and Hepascore have been compared with TE and/or ARFI and LB for initial evaluation of liver fibrosis in HCV patients [9] . They have compared favorably, although some are difficult to calculate and others use specialized expensive commercially produced markers. However, APRI and FIB4 are more accessible and easier to apply than others. As TE and ARFI show a representative result of different parts of the liver, accuracy studies have been developed to evaluate performance compared to LB, which evaluates only a small sample of the liver. As the best cutoff points of each fibrosis stage varies according to different cirrhosis etiologies and populations, these cutoff points need to be validated.
The aim of this study is to identify optimal cutoff values for TE, ARFI, APRI and FIB4 compared with LB in a Brazilian HCV cohort, according to levels of sig nificant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3) and cirrhosis (F = 4).
MATERIALS AND METHODS

Ethical considerations
The Ethics Committee of the Hospital das Clínicas (CAPPesq number 1276/09) reviewed and approved this study, that was conducted following the ethical guidelines of the 1975 Declaration of Helsinki. The requirement for informed written consent was waived.
Study design
We performed an observational study of diagnostic accuracy for TE, ARFI, APRI and FIB4 compared with LB. Figure  1 . Seven patients without LB, but with clinical signs of portal hypertension and cirrhosis (Metavir F = 4) were included. In the end, 81 were selected for the study. Three patients had hepatocellular carcinoma, with less than 2 cm. They were included in the study.
Clinical and biological data
Anthropometric, clinical and laboratorial data were co llected: Gender, age, weight, height, body mass index (BMI), smoking status, alcohol consumption, hypertension, diabetes, dyslipidemia, and serum enzymes such as AST, ALT, bilirubin, albumin, glucose levels and platelet count, all taken from medical charts.
Transient elastography
LSM were performed using the FibroScan ® 402 device powered by VCTE (EchoSens, Paris, France), equipped with the standard M probe. The examination procedure have been previously described [911] . A valid LSM ex amination included 10 valid measurements, a success rate of 70%, and an interquartile range of measurements (IQR) below 30% of the median value. Controlled attenuation parameter (CAP) was also evaluated.
ARFI
ARFI technology measures the shear wave speed in a precise anatomical region, with a predefined size, provided by the system. Measurement value and depth are also reported and elasticity results are represented in m/s [12] . ARFI elastography was performed using a Siemens Acuson S2000
® ultrasound system, a Virtual Touch ® quantification elastography technology (Siemens AG, Erlangen, Germany). The patients were examined in dorsal decubitus, with the right arm in maximum abduction. Scans were performed in a right inferior intercostal space over the right liver lobe (e.g., segment 8), 2 cm under the capsule, with minimal scanning pressure applied by the operator, while patients were asked to stop breathing temporarily. Ten measurements per patient were performed and a median and IQR values were calculated by the machine. Only when an IQR 30% was reached was the median value accepted.
APRI and FIB-4
APRI and FIB4 were calculated through the following scores: APRI score = {[AST/upper limit of normal (ULN)] 100}/platelet count 10
LB
LB was performed in all but 7 patients, who had clinical or ultrasonographic signs of portal hypertension and cirrhosis. They were judged to have Metavir F4 histology. The LB was guided with 14 G TruCut needle (Medical Technology, Gainsville, FL, United States). LB fragments including at least 10 portal tracts were considered adequate for pathological interpretation, and were included in our study. Liver specimens were fixed in formalin and embedded in paraffin. Two micron sections were stained with hematoxylineosin, Masson's trichrome and Sirius red for histological assessment. The liver biopsies were assessed according to the METAVIR score, by a senior pathologist and classified as: F0 -no fibrosis; F1 -portal fibrosis without septa; F2 -portal fibrosis and few septa extending into lobules; F3 numerous septa extending to adjacent portal tracts or terminal hepatic venules and F4 cirrhosis.
Statistical analysis
Statistical analyses were performed by using R statistics . The STARD Statement guidelines were followed. Quantitative characteristics were expressed as mean (SD), median (first and third quartile) and range. Variables were compared using nonparametric Wilcoxon test. P value < 0.05 was considered significant.
The ANOVA or KruskalWallis tests were used for comparison of two or more groups, whether or not the data were normally distributed, respectively. We set that mild disagreement was when only one class was different, and severe disagreement when two or more class were wrongly misclassified.
The diagnostic performance of FibroScan ® , ARFI, APRI and FIB4 tests was assessed using receiver operator curves (ROC). The optimum cutoff levels, defined as area under ROC (AUROC), of each test was chosen to define fibrosis stages F ≥ 2, F ≥ 3 and F = 4. The Kappa index set the concordance analysis. The best sensitivity values (> 80%) have been chosen in order to identify all HCV patients with METAVIR F ≥ 3 (prioritized for treatment according to Brazilian Ministry of Health recommendations) [13] . Positive and negative predictive values (PPV and NPV) were calculated using the prevalence of liver fibrosis stages (F > 2) in the Hepatology Outpatient Center from Hospital das Clinicas of the University of Sao Paulo School of Medicine, Brazil. A statistical review of the study was performed by a biomedical statistician (João Ítalo França).
RESULTS
A total of 81 patients with HCV were included, 41 (50.6%) were female. Anthropometric and laboratorial chara cteristics are shown in Table 1 . The median age was 51 years (3078). Eleven (13.6%) patients had diabetes, 22 (27.2%) hypertension, 20 (24.7%) were smokers and 11 (13.6%) consumed alcohol (> 20 g /d). The median BMI was 26.5 (24.329.6), and 70% of the patients were HCV treatmentnaïve. Most of the patients had Metavir F1 on LB fibrosis stage (33 patients, 40.7%), followed by F2 (20 patients, 24.7%). The mean success rate of TE was 92%.
The best cutoff values of each test (LSM and SM) are found in Table 2 . For predicting F ≥ 2 stage fibrosis with TE was 6.6 kPa, for ARFI 1.22 m/s, for APRI 0.75 and for FIB4 1.47. For F ≥ 3, TE was 8.9 kPa, ARFI was 1.48 m/s, APRI was 0.75, and FIB4 was 2. For F = 4, TE was 12.2 kPa, ARFI was 1.77 m/s, APRI was 1.46, and FIB4 was 3.91. The APRI could not distinguish between F2 and F3 (P = 0.92). The NPV for F = 4 for TE and ARFI was 100%. Kappa Index values for F ≥ 3 METAVIR score for TE, ARFI and FIB4 were 0.687, 0.606 and 0.654, respectively. This demonstrates strong concordance between the TE, ARFI and FIB4 methods, but moderate concordance between them and APRI (Kappa index = 0.507). Figure 2 shows the rate of agreement of TE, ARFI, APRI and FIB4 according to Metavir stage on LB. Since alcohol consumption and severity of liver inflammation could affect TE measurements, patients were also analyzed individually. Of the 11 patients with alcohol consumption, 2 patients had discordant results between TE and liver biopsy. One had Metavir F1A1 and TE of 10 kPa and the other had Metavir F1A2 and TE of 16.3 kPa. With regard to patients with more intense inflammatory activity on hepatic biopsy (Metavir A3-4), we had 6 patients with Metavir A3, and none with Metavir A4. Of these Metavir A3 patients, 5 were Metavir F3 and 1 had cirrhosis. TE discordance with liver biopsy could be found in all Metavir F3A3 patients, with overestimation of TE results (mean TE results: 25.3 kPa). One Metavir F3A3 patient had ALT of 148 U/L and a TE of 28. 4 
DISCUSSION
Our results show that three methods, ARFI, TE and FIB4, independently identify advanced fibrosis. Noninvasive methods have been studied and compared to other methods of liver fibrosis evaluation in order to diminish complications of liver biopsy and costs involved [8] . We evaluated the AUROC and the interagreement of LSM (TE and ARFI) as well as SM (APRI and FIB4) compared with liver biopsy in a population of HCVinfected patients. The best cut-offs were established based on METAVIR fibrosis stages F ≥ 2, F ≥ 3 and F = 4, considering not only the recent international consensus (EASLALEH 2015) but the recommendation for HCV treatment in Brazil, which prioritize F ≥ 3 patients according to the 2015 Brazilian Protocol for HCV treatment [4, 8, 13] . The results of this study do not conflict with previous findings ( Table  2 ). The TE sensitivity (Se) and specificity (Sp) in a recent FibroScan ® metaanalysis [14] ranged from about 0.70 and 0.81 for F ≥ 2, 0.80 and 0.85 for F ≥ 3, and from 0.86 and 0.88 for F = 4. These are similar to our results.
Although TE had better results for F ≥ 2, the overall accuracy for ARFI and TE were comparable, as previously demonstrated by Crespo et al [15] . For the F4 group we found an almost perfect correlation between ARFI, TE and FIB-4, suggesting that only one method is sufficient to identify cirrhosis. It is important to note that on 2 out of 11 patients who reported alcohol consumption (> 20 g/d), TE values were overestimated. The influence of alcohol intake on liver stiffness measurement should be taken into account when interpreting TE results, as shown by BardouJacquet et al [16] . Hepatic inflammation can also be a confounding factor when evaluating liver fibrosis by TE [17] . We could demonstrate that all Metavir F3A3 patients had overestimation of liver fibrosis by TE, with median values of 25.3 kPa.
APRI is a good reproducible marker of cirrhosis, with a high applicability (> 95%), it is easy to perform and is a nonpatented score [18] . In our study APRI could not differentiate between F = 2 and F = 3. This is possibly because it uses fewer variables than FIB4. APRI uses AST and platelet count, while FIB4 also incorporates ALT and age of the patient.
The F2 group is less clearly defined than other stages of fibrosis, as shown in the literature by Rizzo et al [19] , and all methods identified it less accurately. In our study however, there was less disagreement than Afdhal et al [20] which shows that for F2 group, application of both methods, TE and ARFI are necessary to identify these patients. Although LB is the reference standard, its repro ducibility is poor, owing to heterogeneity in liver fibrosis, operator bias and sample size. This can account for an margin of error of up to 20% in disease staging [20] . A limitation of this study is that it identifies and selects cutoff points, but is not prospectively validated, warranting further studies to confirm these results. However, from this study, we can consider that a com bined use of FibroScan ® and FIB4 or FibroScan ® and ARFI in the followup of HCV patients can be a surrogate for fibrosis assessment through LB, which can be held in reserve for cases with significant diagnostic doubt. This is especially important in the intermediate stages of fibrosis (F2 and F3), where each individual noninvasive method is not sufficiently accurate to make a diagnosis, and so should be performed in combination. Further studies are necessary to identify whether they should be performed simultaneously or in parallel, and identify the best cutoffs for each combination of methods.
In conclusion, given the higher cost and reduced accessibility of LSM methods, and the similarity with the outcomes of SM in evaluation of liver fibrosis, we suggest that FIB4 used alongside TE and ARFI may be good tools for the prediction of severity of liver fibrosis. This may be of particular importance to developing countries. 
COMMENTS
Background
The evaluation of liver fibrosis is not a simple task and demands the use of different methods. Liver stiffness measurement (LSM) and serum markers (SM) provide a non-invasive source of diagnosis with good correlation with the gold standard method, liver biopsy.
Research frontiers
The F2 group is less clearly defined than other stages of fibrosis. In the authors' study there was however less disagreement, which shows that for F2 group, application of both methods, transient elastography (TE) and acoustic radiation force impulse (ARFI) is necessary to identify these patients. Further studies are necessary to identify whether they should be performed simultaneously or in parallel, and identify the best cutoffs for each combination of methods.
Innovations and breakthroughs
This results show that three methods, ARFI, TE and FIB-4, independently identify advanced fibrosis.
Applications
Given the higher cost and reduced accessibility of LSM methods, and the similarity with the outcomes of SM in evaluation of liver fibrosis, the authors suggest that FIB-4 used alongside TE and ARFI may be good tools for the prediction of severity of liver fibrosis. This may be of particular importance to developing countries.
Terminology
Non-invasive tests for liver fibrosis evaluation: (1) Mechanical markers: liver stiffness measurement according to transient elastography (FibroScan ® ) or ARFI; and (2) Serum markers: Aspartate aminotransferase-to-platelet ratio index (APRI) and FIB-4 (based on age, platelet count, aspartate aminotransferase and alanine aminotransferase). Liver biopsies were assessed according to the METAVIR score classified as: F0 -no fibrosis; F1 -portal fibrosis without septa; F2 -portal fibrosis and few septa extending into lobules; F3 -numerous septa extending to adjacent portal tracts or terminal hepatic venules and F4 -cirrhosis.
Peer-review
This study is addressed to evaluate the diagnostic performance and the concordance of different noninvasive methods for the evaluation of liver fibrosis (APRI, FIB-4, transient elastography, ARFI) in 81 patients with chronic hepatitis C, most of them with biopsy-proven diagnosis. The authors concluded that FIB-4, ARFI and transient elastography are useful tests for the noninvasive assessment of liver fibrosis, with a good concordance.
